This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
2 Medical Stocks to Consider Buying in June
by Shaun Pruitt
With solid top and bottom-line growth on the horizon for HealthEquity (HQY) and iRadimed (IRMD), they are starting to look like viable investments for 2023 and beyond.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Bristol Myers (BMY) Heart Drug Camzyos Wins EC Approval
by Zacks Equity Research
Bristol Myers (BMY) receives EC approval for Camzyos for treating symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.
Bristol Myers Squibb (BMY) Stock Moves -0.4%: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $65.04, marking a -0.4% move from the previous day.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Bristol Myers (BMY) Announces CAR T Cell Therapy Breyanzi Data
by Zacks Equity Research
Bristol Myers' (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel) shows deep and durable responses in relapsed or refractory follicular lymphoma and mantle cell lymphoma.
Bristol Myers (BMY) Gets FDA Nod for Data Addition to Camzyos
by Zacks Equity Research
Bristol Myers (BMY) receives FDA approval for additional data to be added to the label of the heart drug Camzyos.
2seventy (TSVT) Down 9% on Patient Death in Leukemia Study
by Zacks Equity Research
Following a patient's death, investigators pause an early-stage study on 2seventy bio's (TSVT) CAR-T cell therapy in AML indication. However, it is still unclear whether the death was due to the treatment.
Bristol Myers Squibb (BMY) Flat As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $64.76, marking no change from the previous day.
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $65.16 in the latest trading session, marking a -0.49% move from the prior day.
Legend (LEGN) Up 4% on sNDA Submission for Carvykti Expanded Use
by Zacks Equity Research
Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with relapsed and lenalidomide-refractory multiple myeloma. Stock rises 4% following the news.
Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study
by Zacks Equity Research
Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy of Opdivo plus Yervoy.
The Zacks Analyst Blog Highlights NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance
by Zacks Equity Research
NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance are included in this Analyst Blog.
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $64.68, moving +0.37% from the previous trading session.
Top Analyst Reports for NVIDIA, Bristol-Myers Squibb & ICICI Bank
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Bristol-Myers Squibb Company (BMY) and ICICI Bank Limited (IBN).
Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?
by Zacks Equity Research
Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.
Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More
by Zacks Equity Research
Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.
Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review
by Zacks Equity Research
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug
by Zacks Equity Research
The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.
Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation
by Zacks Equity Research
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
Mirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8%
by Zacks Equity Research
Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.
Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results
by Zacks Equity Research
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.
Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up
by Zacks Equity Research
Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track.
Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up
by Zacks Equity Research
Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focus.